Efficacy and tolerability of valsartan in combination with hydrochlorothiazide in essential hypertension

被引:21
作者
Hall, WD
Montoro, R
Littlejohn, T
Jain, A
Feliciano, N
Zheng, HJ
机构
[1] Hypertens Res Ctr, Decatur, GA 30030 USA
[2] Clin Therapeut Corp, Coral Gables, FL USA
[3] Piedmont Res Assoc, Winston Salem, NC USA
[4] Clin Res Ctr, New Orleans, LA USA
[5] Novartis Pharmaceut, Summit, NJ USA
关键词
D O I
10.2165/00044011-199816030-00004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: This study compared the efficacy and tolerability of two combination regimens of valsartan and hydrochlorothiazide (HCTZ) with valsartan monotherapy in patients with essential hypertension inadequately controlled with valsartan 80mg once daily. Patients and Methods: A total of 708 patients with inadequately controlled blood pressure after 4 weeks' treatment with valsartan 80mg once daily participated in this double-blind comparative trial. Patients were randomly allocated once-daily treatment with valsartan 80mg, valsartan 160mg, valsartan 80mg + HCTZ 12.5mg or valsartan 80mg + HCTZ 25mg for 8 weeks. Results: Statistically significant decreases in mean sitting diastolic blood pressure (SDBP) and mean sitting systolic blood pressure (SSBP) from baseline were seen in all treatment groups (least squares mean change from baseline SDBP: -5.1mm Hg, -6.2mm Hg, -8.2mm Hg, -10.8mm Hg; SSBP: -3.9mm Hg, -6.5mm Hg, -9.8mm Hg, -16.0mm Hg for valsartan 80mg, valsartan 160mg, HCTZ 12.5mg combination, HCTZ 25mg combination, respectively). A significant difference for mean SDBP, SSBP and responder rates in favour of the combination regimens was observed compared with either valsartan monotherapy. All treatments were well tolerated with the percentage of patients reporting treatment-related adverse experiences at any time ranging from 9.9% (valsartan 160mg) to 21.0% (HCTZ 25mg combination). Conclusion: The study demonstrated that a combination of valsartan 80mg and HCTZ 12.5mg or 25mg provides an effective and well tolerated treatment in patients who need additional blood pressure control beyond valsartan monotherapy.
引用
收藏
页码:203 / 210
页数:8
相关论文
共 18 条
[1]  
[Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI DOI 10.1001/ARCHINTE.1997.00440420033005
[2]   Valsartan, a new angiotensin II receptor antagonist: A double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide [J].
Benz, J ;
Oshrain, C ;
Henry, D ;
Avery, C ;
Chiang, YT ;
Gatlin, M .
JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 37 (02) :101-107
[3]   Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril [J].
Black, HR ;
Graff, A ;
Shute, D ;
Stoltz, R ;
Ruff, D ;
Levine, J ;
Shi, Y ;
Mallows, S .
JOURNAL OF HUMAN HYPERTENSION, 1997, 11 (08) :483-489
[4]   Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine [J].
Corea, L ;
Cardoni, O ;
Fogari, R ;
Innocenti, P ;
Porcellati, C ;
Provvidenza, M ;
Meilenbrock, S ;
Sullivan, J ;
Bodin, F .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (03) :341-346
[5]   PHARMACOLOGICAL PROFILE OF VALSARTAN - A POTENT, ORALLY-ACTIVE, NONPEPTIDE ANTAGONIST OF THE ANGIOTENSIN-II AT1-RECEPTOR SUBTYPE [J].
CRISCIONE, L ;
DEGASPARO, M ;
BUHLMAYER, P ;
WHITEBREAD, S ;
RAMJOUE, HPR ;
WOOD, J .
BRITISH JOURNAL OF PHARMACOLOGY, 1993, 110 (02) :761-771
[6]   Newer approaches to antihypertensive therapy - Use of fixed-dose combination therapy [J].
Epstein, M ;
Bakris, G .
ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (17) :1969-1978
[7]  
FRISHMAN WH, 1987, J CLIN HYPERTENS, V3, P520
[8]   The angiotensin II type 1 receptor blocker losartan in clinical practice: A review [J].
Gavras, HP ;
Salerno, CM .
CLINICAL THERAPEUTICS, 1996, 18 (06) :1058-1067
[9]   Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy and safety compared to hydrochlorothiazide [J].
Hegner, G ;
Faust, G ;
Freytag, F ;
Meilenbrock, S ;
Sullivan, J ;
Bodin, F .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 52 (03) :173-177
[10]   Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy and safety compared with placebo and enalapril [J].
Holwerda, NJ ;
Fogari, R ;
Angeli, P ;
Porcellati, C ;
Hereng, C ;
OddouStock, P ;
Heath, R ;
Bodin, F .
JOURNAL OF HYPERTENSION, 1996, 14 (09) :1147-1151